PMID- 23560372
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20181202
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 9
IP  - 4
DP  - 2013 Apr
TI  - Selection and management of hepatocellular carcinoma patients with sorafenib: 
      recommendations and opinions from an Italian liver unit.
PG  - 485-91
LID - 10.2217/fon.12.208 [doi]
AB  - Sorafenib (SO) was the first systemic agent to demonstrate a significant 
      improvement in overall survival in patients with advanced hepatocellular 
      carcinoma (HCC); international guidelines now recommend SO as a first-line 
      treatment in patients with unresectable HCC who are not eligible for locoregional 
      therapies and maintain preserved liver function. However, therapy with SO may 
      require close management to further optimize the clinical outcomes and limit the 
      onset of adverse events (AEs). SO has been in use at our Liver Unit (Avellino, 
      Italy) for over 4 years, and in that time 85 patients with HCC have been treated 
      with SO. Here we describe how patients with HCC are managed with SO in our unit 
      where management is based on three pivotal strategies: targeted patient 
      selection; use of dose escalation to increase compliance and reduce AEs; and 
      adoption of measures to prevent and manage AEs and to provide open access for 
      patients.
FAU - D'Angelo, Salvatore
AU  - D'Angelo S
AD  - Liver Unit, Clinical & Experimental Hepatology, Department of Internal Medicine, 
      SG Moscati Hospital, Avellino, Avellino Contrada Amoretta 83100, Italy.
FAU - Secondulfo, Mario
AU  - Secondulfo M
FAU - De Cristofano, Raffaele
AU  - De Cristofano R
FAU - Sorrentino, Paolo
AU  - Sorrentino P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Diarrhea/chemically induced
MH  - Dose-Response Relationship, Drug
MH  - Fibrosis/drug therapy
MH  - Hepatitis B/complications/drug therapy
MH  - Hepatitis C/complications/drug therapy/virology
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Italy
MH  - Liver Cirrhosis/drug therapy/virology
MH  - Liver Neoplasms/*drug therapy
MH  - Middle Aged
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Patient Selection
MH  - Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Sorafenib
MH  - Weight Loss/drug effects
EDAT- 2013/04/09 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/04/09 06:00
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.2217/fon.12.208 [doi]
PST - ppublish
SO  - Future Oncol. 2013 Apr;9(4):485-91. doi: 10.2217/fon.12.208.